Nitric oxide-inhibited chloride transport in cortical thick ascending limbs is reversed by 8-iso-prostaglandin-F2α

Background: Salt reabsorption in the cortical thick ascending limb (cTAL) is regulated by opposing effects. Thus, while nitric oxide (NO) inhibits sodium chloride (NaCl) reabsorption, 8-iso-prostaglandin-F2α (8-iso-PGF2α) stimulates it. Their interaction, however, has not been evaluated in the cTAL. Because 8-iso-PGF2α has considerable stability while NO is a free radical with a short half-life, we hypothesized that, in the cTAL, the inhibition of NaCl absorption will be reversed by 8-iso-PGF2α. Methods: Chloride absorption (JCl) was measured in isolated perfused cTALs. We also evaluated whether activation of protein kinase A (PKA) is required for this interaction. Since cyclic adenosine monophosphate (cAMP) is a major messenger for the 8-iso-PGF2α signaling cascade, and NO inhibits JCl by decreasing cAMP bioavailability, we measured 8-iso-PGF2α-stimulated cAMP in the presence of sodium nitroprusside (SNP). Results: Basal JCl was 274 ± 85 pmol/min/mm. The NO donor, SNP (10-6 M), decreased JCl by 41% (333.5 ± 35.2 pmol/min/mm vs. 195.9 ± 26.1 pmol/min/mm), while 8-iso-PGF2α (100 μM) increased JCl to 315 ± 46 pmol/min/mm (p \u3c 0.01), reversing the effects of the NO donor. While SNP inhibited JCl, 8-iso-PGF2α failed to increase JCl in the presence of H89. Basal cAMP was 56.3 ± 13.1 fmol/min/mm, that in the presence of the NO donor was 57.8 ± 6.1 fmol/min/mm, and that with 8-iso-PGF2α increased it to 92.1 ± 2.9 fmol/min/mm (n = 10, p \u3c 0.04). Conclusion: We concluded that 1) NO-induced inhibition of JCl in the cTAL can be reversed by 8-iso-PGF2α, 2) 8-iso-PGF2α and NO interaction requires PKA to control JCl in this nephron segment, and 3) in the presence of NO, 8-iso-PGF2α continues to stimulate JCl because NO cannot reverse 8-iso-PGF2α-stimulated cAMP level

Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency

Oxidative stress and inflammation seem to mediate the cardiovascular risks associated with salt sensitivity. Because hydroxymethyl glutaryl coenzyme A reductase inhibitors decrease oxidation and increase nitric oxide (NO) synthesis, we examined the effects of atorvastatin (ator) on tissue injury in rats with a reduced renal mass produced by 5/6 nephrectomy. This salt-sensitive hypertension model causes kidney and cardiovascular injuries. Methods: After undergoing 5/6 nephrectomy or sham surgery, male Sprague-Dawley rats were randomized into five groups: sham, reduced renal mass and a normal salt diet (NNaD), NNaD+ator (50 mg · kg-1 · d-1), reduced renal mass and a high salt diet (HNaD), and HNaD+ator. After assessing the sodium balance for 7 d, we measured blood pressure (BP), creatinemia, proteinuria, nitrites, and 12(S)-hydroxy 5,8,10-heptadecatrienoic acid, the renal cortical expression of endothelial NO synthase, and the ratio of left ventricular weight to body weight. Results: In NNaD rats, creatinine, proteinuria, and 12(S)-hydroxy 5,8,10-heptadecatrienoic acid increased, renal NO indices decreased, but the Na+ balance, BP, and the left ventricular weight/body weight ratio remained unchanged. In the NNaD group, atorvastatin normalized the NO indices and decreased BP and proteinuria, although the remaining parameters continued unchanged. In contrast, HNaD increased creatinemia, proteinuria, and 12(S)-hydroxy 5,8,10-heptadecatrienoic acid excretion rates and decreased renal endothelial NO synthase. Salt retention was accompanied by increased BP and ventricular weight. In this HNaD group, atorvastatin prevented a BP increase, partly decreased sodium retention, but failed to improve NO indices, proteinuria, oxidant stress, and the left ventricular weight/body weight ratio. Atorvastatin exerts beneficial effects on renal function, injury, and salt sensitivity in rats with a reduced renal mass on an NNaD. The HNaD hampers these beneficial effects.Fil: Juncos, Luis Isaias. Fundación J. Robert Cade; Argentina. Universidad Nacional de Córdoba; Facultad de Medicina.; ArgentinaFil: Martín, Fernando L. Mayo Clinic and Foundation; Estados UnidosFil: Baigorria, Sandra T.. Fundación J. Robert Cade; ArgentinaFil: Pasqualini, María Eugenia. Universidad Nacional de Córdoba; Facultad de Medicina.; ArgentinaFil: Fiore, María C.. Fundación J. Robert Cade; ArgentinaFil: Eynard, Aldo Renato. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Juncos, Luis A.. University of Mississippi; Estados UnidosFil: Garcia, Nestor Horacio. Fundación J. Robert Cade; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentin